USPTO serial 97427897
INOVIQ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 16, 2026
- Examiner
- BRUNDAGE, DAVID WILLIAM
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INOVIQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Notting Hill, VIC, AU
Notting Hill, VIC, AU
Notting Hill, VIC, AU
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles G. Zug
Charles G. Zug NELSON MULLINS RILEY & SCARBOROUGH LLP301 SOUTH COLLEGE STREETSUITE 2300, IP DEPARTMENTCHARLOTTE, NC 28202Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biological reagents for scientific and research use for molecular targets for drug and vaccine development; reagents for medical research applications; reagents for medical research applications, namely, molecular targets for drug and vaccine development; biological reagents for use in molecular biology for research purposes; reagents for medical diagnosis research applications | ACTIVE | — |
| 005 | Pharmaceutical, biotechnology and medical preparations and substances for the prevention, diagnosis or treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases; pharmaceutical, biotechnology and medical preparations and substances for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; diagnostic preparations and reagents for medical purposes; diagnostic preparations for medical laboratory use and reagents for medical purposes, namely, extracellular vesicles, RNA, protein arrays or monoclonal antibodies; monoclonal antibodies for medical purposes; monoclonal antibody fragments for medical purposes; monoclonal antibody conjugates for medical purposes; preparations for the treatment, reconstruction and repair of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases using antibodies or exosomes; immunological antibodies for medical use; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical purposes; biological preparations for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for pharmaceutical purposes; biological substances for the treatment of cancer, neurodegenerative, cardiovascular, inflammatory, and metabolic diseases for medical use; monoclonal antibodies for diagnostic medical use; monoclonal antibodies for medical use; monoclonal antibodies for therapeutic purposes; products containing monoclonal antibodies for use in medicine; proteins for medical use in binding antibodies; proteins for medical use in detecting antibodies; reagents for use in the development of monoclonal antibodies for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral or bacterial infection; vaccines for human use; vaccine adjuvants; diagnostic preparations, reagents, pharmaceutical and biochemical anti-cancer substances, products for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases, and testing materials, namely, diagnostic test strips, immunoassays, PCR or genetic tests for in-vitro diagnostic use for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic biomarker reagents for medical purposes; reagents for use in diagnostic tests for medical purposes; protein arrays for use in recombinant DNA technology for medical diagnosis purposes; biological reagents for use in molecular biology for medical purposes; diagnostic preparations and reagents for medical purposes, namely, diagnostic reagents for in-vitro use for medical purposes, reagents for in-vitro laboratory use for medical purposes, reagents for use in diagnostic tests for medical purposes, diagnostic reagents for medical use for sale in kit form; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical purposes; pharmaceutical, biotechnology and medical preparations and substances for medical use, namely, immunotherapeutic agents for the treatment of cancer; nucleic acid substances for use in genetic probe assay kits for medical use; preparations for the treatment, reconstruction and repair of antibodies, namely, biological preparations for pharmaceutical purposes | ACTIVE | — |
| 010 | Biotechnology medical apparatus for the prevention, diagnosis or treatment of cancer, neurodegenerative, inflammatory, and metabolic diseases; medical diagnostic apparatus and instruments for testing biofluids, plasma, serum, saliva, urine and cell cultures for sale in kit form; biotechnology medical apparatus, namely, medical apparatus for the capture of extracellular vesicles | ACTIVE | — |
| 042 | Scientific research, clinical research, development, advisory and consultancy services in relation to antibody production; vaccine screening, in the nature of research and development of vaccines; advisory services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; providing diagnostic testing services for others for scientific research purposes; scientific research for medical purposes; scientific research for medical purposes, namely, research services relating to diagnostic products for scientific research, extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; diagnostic and research services and screening in the nature of research services in the field of diagnostic preparations; preparation of reports relating to medical, scientific and technical research; provision of information relating to medical, scientific and technical research; research and development of products; research and development of products, namely, new therapeutic products in the field of gene therapeutics and cell therapeutics; research and development of products, namely, extracellular vesicle-based diagnostic products, extracellular vesicle-based therapeutic products; laboratory research in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; laboratory research services relating to research in the field of extracellular vesicle-based diagnostics and extracellular vesicle-based therapeutics; scientific laboratory research and analysis services; scientific laboratory research and analysis services for research and analysis of new products in the field of cell therapeutics; analysis of tissues for medical research; research and development services in the field of antibody generation; molecular target discovery and development services; recombinant human protein production cell line, namely, culturing of cells for others for scientific research purposes | ACTIVE | — |
| 044 | Advisory services relating to medical diagnostic products; advisory services relating to medical diagnostic products, namely, medical diagnostic products for extracellular vesical (EV) isolations, creating custom NET builds, or developing diagnostic assays; Medical diagnostic testing services; medical diagnostic screening services in the field of diagnostic preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by INOVIQ Limited
- Other trademarks owned by INOVIQ Limited
- Other trademarks owned by INOVIQ Limited
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named INOVIQ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 16, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 28, 2026 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| May 27, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 6, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 27, 2025 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| May 27, 2025 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 26, 2024 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 15, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 15, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 25, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 12, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 12, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 12, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 12, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 12, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jun 11, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jun 11, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 12, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 12, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 12, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 12, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 12, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 12, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 12, 2024 | ALIE | ASSIGNED TO LIE | — |
| Sep 21, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 21, 2023 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Jun 20, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Jun 20, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Mar 21, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 21, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 10, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 2, 2022 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 1, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 28, 2022 | NWAP | NEW APPLICATION ENTERED | — |